Follow
Veli Berk
Veli Berk
Kayseri Memorial Hastanesi
Verified email at memorial.com.tr
Title
Cited by
Cited by
Year
Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study
MG Kaya, M Ozkan, O Gunebakmaz, H Akkaya, EG Kaya, M Akpek, ...
International journal of cardiology 167 (5), 2306-2310, 2013
3572013
Protective effects of spironolactone against anthracycline‐induced cardiomyopathy
M Akpek, I Ozdogru, O Sahin, M Inanc, A Dogan, C Yazici, V Berk, ...
European journal of heart failure 17 (1), 81-89, 2015
2352015
Outcome of non-metastatic male breast cancer: 118 patients
ÜY Arslan, B Öksüzoğlu, N Özdemir, S Aksoy, N Alkış, A Gök, MA Kaplan, ...
Medical Oncology 29, 554-560, 2012
872012
Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer
M Inanc, M Ozkan, H Karaca, V Berk, O Bozkurt, AO Duran, E Ozaslan, ...
Medical oncology 31, 1-8, 2014
712014
Albumin-globulin ratio for prediction of long-term mortality in lung adenocarcinoma patients
AO Duran, M Inanc, H Karaca, I Dogan, V Berk, O Bozkurt, E Ozaslan, ...
Asian Pacific Journal of Cancer Prevention 15 (15), 6449-6453, 2014
652014
Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
B Cetin, V Berk, MA Kaplan, B Afsar, G Tufan, M Ozkan, A Isikdogan, ...
Clinical genitourinary cancer 11 (2), 141-148, 2013
512013
Factors affecting prognosis in metastatic colorectal cancer patients
B Eker, E Ozaslan, H Karaca, V Berk, O Bozkurt, M Inanc, AO Duran, ...
Asian Pacific Journal of Cancer Prevention 16 (7), 3015-3021, 2015
412015
Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients
O Bozkurt, H Karaca, V Berk, M Inanc, AO Duran, E Ozaslan, M Ucar, ...
JBUON 12, 14, 2015
402015
Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients
H Demiraslan, M Sevim, Ç Pala, S Durmaz, V Berk, L Kaynar, G Metan
International journal of hematology 97, 414-420, 2013
392013
Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients
H Demiraslan, M Sevim, Ç Pala, S Durmaz, V Berk, L Kaynar, G Metan
International journal of hematology 97, 414-420, 2013
392013
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology
V Berk, MA Kaplan, O Tonyali, S Buyukberber, O Balakan, M Ozkan, ...
Asian Pacific Journal of Cancer Prevention 14 (12), 7367-7369, 2013
382013
Treatment regimen with bevacizumab decreases mean platelet volume in patients with metastatic colon cancer
H Mutlu, V Berk, H Karaca, A Erden, T Aslan, Z Akca
Clinical and Applied Thrombosis/Hemostasis 18 (5), 546-548, 2012
382012
Prevalence of Encephalitozoon intestinalis and Enterocytozoon bieneusi in cancer patients under chemotherapy
B Hamamcı, Ü Çetinkaya, V Berk, L Kaynar, S Kuk
Mikrobiyoloji bulteni 49 (1), 105-113, 2015
372015
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents
B Cetin, M Kaplan, V Berk, S Ozturk, M Benekli, A Isikdogan, M ÖZKAN, ...
Asian Pacific Journal of Cancer Prevention 13 (3), 2012
372012
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience
M ÖZKAN, V Berk, M Kaplan, M Benekli, U Coskun, A Bilici, M Gumus, ...
Neoplasma 59 (1), 2012
362012
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)
B Cetin, M Benekli, I Turker, L Koral, A Ulas, F Dane, B Oksuzoglu, ...
Journal of chemotherapy 26 (5), 300-305, 2014
352014
XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer
V Berk, N Ozdemir, M Ozkan, S Aksoy, N Turan, A Inal, O Balakan, ...
Hepatogastroenterology 59 (120), 2635-9, 2012
322012
D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer
M Inanc, O Er, H Karaca, V Berk, M Ozkan, M Dikilitas, F Elmali
J buon 18 (2), 391-397, 2013
312013
Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer
N Turan, M Benekli, D Koca, BO Ustaalioglu, F Dane, N Ozdemir, A Ulas, ...
Oncology 84 (1), 14-21, 2012
282012
Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer
M Ozkan, IH Akbudak, K Deniz, M Dikilitas, GG Dogu, V Berk, H Karaca, ...
Asian Pac J Cancer Prev 11 (1), 181-185, 2010
282010
The system can't perform the operation now. Try again later.
Articles 1–20